Why is the mortality rate of pancreatic cancer is soo high?

Share This Post

The pancreas is an oblong organ located deep in the abdomen and is a component of the digestive system and endocrine system. It secretes hormones to regulate the body and secretes digestive enzymes to break down food. There are two types of pancreatic cancer: exocrine tumors and endocrine tumors. Exocrine tumors are the main part of pancreatic cancer. The most common form is called adenocarcinoma. Adenocarcinoma begins in glandular cells, usually in the pancreatic duct. These tumors are often more aggressive than neuroendocrine tumors. According to the National Cancer Institute, pancreatic cancer can usually be controlled only by surgical resection and before the cancer has spread. If the disease spreads, palliative care can help the patient’s quality of life.

Third leading cause of cancer death in the United States after lung cancer and colorectal cancer. The risk of disease is about 63% for men and 65% for women. According to data from the American Cancer Society, approximately 55,440 people will be diagnosed with pancreatic cancer this year, which will result in approximately 44,330 deaths. Experts say that about 95% of pancreatic cancer patients will die from pancreatic cancer. Because pancreatic cancer is at an early stage, there are usually no symptoms. It is often discovered when abdominal pain or jaundice appears late. As people age, the risk of pancreatic cancer also increases. Men are slightly more likely to develop pancreatic cancer than women, which may be partly due to more men who smoke. In addition, related to race, African Americans are more prone to pancreatic cancer than Caucasians.

Studies have shown that diabetes after the age of 50 may be an early sign of pancreatic cancer, and pancreatic neuroendocrine tumors account for only 1% of all pancreatic cancers. It may be benign or malignant, but sometimes it can only be clearly distinguished when the cancer has spread beyond the pancreas. The five-year survival rate of neuroendocrine tumors can be between 50% and 80%, while adenocarcinoma is less than 5%. In addition, there are two rare genetic syndromes, multiple endocrine adenoma type 1 (MEN1) and Von Hippel-Lindau syndrome (VHL), which increase the risk of pancreatic neuroendocrine tumors.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient A case report
CAR T-Cell therapy

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient : A case report

Claudin18.2-targeted CAR-T cell therapy has shown remarkable potential in treating advanced pancreatic cancer, as highlighted in a recent case report. This innovative approach led to complete remission in a patient with advanced disease, underscoring the promise of targeted immunotherapy. By leveraging the specific expression of Claudin18.2 on cancer cells, this therapy offers a precision-based treatment, heralding a new era in pancreatic cancer management with significant clinical implications.

What is the treatment after BCMA CAR T failed in RR multiple myeloma cases
CAR T-Cell therapy

What is the treatment after BCMA CAR T failed in R/R multiple myeloma cases?

For people with relapsed or refractory multiple myeloma, BCMA CAR T-cell therapy might not work. Other treatments, such as bispecific antibodies, other CAR T-cell therapies that target different antigens, and combination regimens with immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies, can still be used. OriCAR-017 is another immunotherapy that is under trial and is expected to be launched soon. Clinical trials offer experimental treatments, providing access to novel therapies. Tailored approaches based on patient-specific factors and emerging research are crucial for improving outcomes in this challenging scenario.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy